INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?
Inspire Medical Systems gains 47.8% in three months as improved reimbursement clarity, an earnings beat, $30 million in annual savings and new CPT codes boost recovery prospects.
Zacks
INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?
Inspire Medical Systems gains 47.8% in three months as improved reimbursement clarity, an earnings beat, $30 million in annual savings and new CPT codes boost recovery prospects.
Zacks
More News
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.
Zacks
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
BD's 25.5% rally reflects stronger execution, portfolio reshaping, product innovation and U.S. manufacturing investments despite tariffs and cost pressures.
Zacks
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here is how Aclaris Therapeutics (ACRS) and Glaukos (GKOS) have performed compared to their sector so far this year.
Zacks
Intuitive Surgical's Q3 Earnings Beat Estimates on Strong System Sales
ISRG's Q3 2026 earnings beat estimates as strong system placements, rising procedure volumes and improving margins fuel double-digit revenue growth.
Zacks
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
Zacks
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.
Zacks
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.read more...
Benzinga
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Zacks
Glaukos Reports Positive Phase 4 Results For IDose TR With Cataract Surgery
(RTTNews) - Friday, Glaukos Corporation (GKOS) announced positive topline results from a Phase 4 study evaluating iDose TR in combination with cataract surgery in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT...